Journal of Clinical Oncology

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Retrieved on: 
Thursday, April 18, 2024
Oncology, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical school, University, Cancer, The Lancet, Journal of Clinical Oncology, Lung cancer, Clinical Cancer Research, NDA, Pancreatic cancer, Hematology, Internal medicine, RAS, Nektar, Leukemia, Patient, Data management, Northeast Ohio Medical University, Blood, Nektar Therapeutics, Therapy, Journal, Verastem Oncology

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.
  • “John is a recognized leader in oncology with broad expertise across cancer research and development, business development and organizational leadership, and we welcome him to the Verastem team,” said Dan Paterson, president and chief executive officer of Verastem Oncology.
  • Dr. Hayslip received his medical degree from Northeast Ohio Medical University and a master’s degree in clinical research from the Medical University of South Carolina.
  • Following his residency in internal medicine, Dr. Hayslip completed his fellowship in hematology-oncology at the Medical University of South Carolina, leading to dual board certifications in both hematology and medical oncology.

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Retrieved on: 
Monday, December 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, City, ASH, CRS, Pros, Patient, Probability, Conference, Bristol Myers Squibb, Prognosis, ORR, Quality of life, Disclosure, Safety, Food, SLL, Jungian cognitive functions, DOR, Trial of the century, Blood, Lymphoma, Society, Bone marrow, Neuropsychological test, Haematopoietic system, BMY, Pain, Journal of Clinical Oncology, NYSE, BTK, MCL, Clinical trial, Fatigue, Follicular lymphoma, PRO, Chronic lymphocytic leukemia, BMS, NHL, CLL, HIV disease progression rates, Pharmaceutical industry, Veterinary medicine, Lisocabtagene maraleucel, Hematology

TRANSCEND FL is the largest clinical trial to date to evaluate a CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including FL.

Key Points: 
  • TRANSCEND FL is the largest clinical trial to date to evaluate a CAR T cell therapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma, including FL.
  • Additionally, the company presented long-term data from the TRANSCEND CLL 004 study evaluating Breyanzi in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) with 24-month follow-up ( Oral Presentation #330 ).
  • Bristol Myers Squibb (BMS) has the broadest ongoing cell therapy development program in CD19-positive malignancies with Breyanzi, which also includes trials investigating its use in patients with relapsed/refractory mantle cell lymphoma (MCL).
  • In the TRANSCEND FL clinical trial, 130 patients with relapsed or refractory follicular lymphoma (FL) were enrolled and treated with Breyanzi in the second-line and third-line plus settings.

City of Hope Vice Physician-in-Chief Edward S. Kim, M.D., M.B.A, Recognized as a Top Diversity Leader in U.S. Healthcare

Retrieved on: 
Monday, November 6, 2023
Oncology, Professional Services, DEI (Diversity, Equity and Inclusion), Health, Clinical Trials, Research, Science, Faculty, Policy, Modern Healthcare, Friends, American Society of Clinical Oncology, City of Hope, Cancer Prevention Research, Lung cancer, Physician, Friends of Cancer Research, Head, State, Organization, The Lancet, Journal, Society, Multimedia, Quality of life, City, Lung, Clinical trial, Diversity, Journal of Clinical Oncology, Cancer Discovery (journal), Patient, ASCO, National Integration Party (Costa Rica), Nature Medicine, Pharmaceutical industry, Hospital, Nursing, Medical imaging, Hope, Cancer, Lancet

City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .

Key Points: 
  • City of Hope, one of the largest cancer research and treatment organizations in the United States, announced today that Vice Physician-in-Chief Edward S. Kim , M.D., M.B.A., has been named a 2023 Modern Healthcare Top Diversity Leader .
  • The prestigious honor recognizes diverse health care executives and organizations influencing policy and care delivery across the country.
  • This is the second time Kim — a renowned lung cancer expert and physician-executive — has earned this recognition.
  • “Ed is deeply committed to ensuring that everyone we serve has equitable access to advanced cancer care,” said Annette Walker, president, City of Hope Orange County.

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Retrieved on: 
Wednesday, October 25, 2023
Trial of the century, Harvard Medical School, Brigham and Women's Hospital, Therapy, Clinical Cancer Research, Prostate cancer, MD, Dana–Farber Cancer Institute, Doctor of Philosophy, HIV disease progression rates, Journal, Internal medicine, Estate (law), Duke University School of Medicine, Abiraterone acetate, Metastasis, SAN, Oncology, Biochemistry, Massachusetts Institute of Technology, Journal of Clinical Oncology, AR, Canisius College, Patient, Hospital, SAB, Massachusetts Institute of Technology School of Engineering, Prostate, The New England Journal of Medicine, Pharmaceutical industry, Medicine, Lancet

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).

Key Points: 
  • SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB).
  • “We wholeheartedly welcome Dr. Smith to Oncternal’s Prostate Cancer Scientific Advisory Board,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO.
  • He has published extensively on the treatment and prevention of bone metastases, prostate cancer survivorship, and novel androgen receptor pathway inhibitors.
  • He completed a fellowship in Medical Oncology at Dana Farber Cancer Institute and a postdoctoral fellowship at Massachusetts Institute of Technology.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Tuesday, October 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

ScreenPoint Medical Showcases Global Momentum for Transpara(R) Breast AI at EUSOBI

Retrieved on: 
Thursday, September 28, 2023
Journal of Clinical Oncology, Risk, The, Mayo Clinic, University, American Journal of Clinical Oncology, Workflow, Breast cancer awareness, Radiology, Breast, Cancer, Risk assessment, Woman, University of California, Density, Journal, Publication, Triage, The Lancet, Breast cancer, Algorithm, Randomized controlled trial, Interval, Artificial Intelligence System, Workload, Artificial intelligence, Diagnosis, Clinical professor, European Society of Radiology, Research, AI, Mammography, Medical device, Medical imaging, European Radiology

VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ScreenPoint Medical is showcasing global momentum for Transpara, the world's leading Breast artificial intelligence (AI) software, here at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, September 28-30, 2023 (Booth M02). 

Key Points: 
  • VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ScreenPoint Medical is showcasing global momentum for Transpara, the world's leading Breast artificial intelligence (AI) software, here at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, September 28-30, 2023 (Booth M02).
  • Headlining the publications are preliminary results from the first randomized controlled trial in Breast AI: the Mammography Screening with AI (MASAI) Study published this summer in Lancet Oncology.
  • Results on prior mammograms with a Transpara score of 10 illustrate the potential for earlier detection of breast cancers by using AI in screen-reading.
  • These studies have validated Transpara's performance in helping radiologists detect cancer earlier and safely reduce workload," said Mark Koeniguer, ScreenPoint Medical CEO.

Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Medical Devices, Health Technology, Other Science, Science, Biotechnology, PROMIS, Journal of Clinical Oncology, United States National Library of Medicine, Prostate, LDT, PMID, BJU International, AIM, National Prostate Health Month, University, Prostate cancer, Abner Doble, Hospital, TRUS, Section, Cancer, UK2, OBD, Large intestine, Mortality, Lung, Penn Presbyterian Medical Center, Protection, MRI, Journal, Patient, Risk, Medicine, BMJ, PSE, Movember, PMCID, NHS, Erectile dysfunction, Death, PSA, News, Biopsy, Dairy, Medical imaging, Urology, Lancet

The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.

Key Points: 
  • The current blood screening test, the PSA test, is only 55% accurate, and is considered an unreliable test by many doctors, including the NHS in the UK2.
  • It feels wholly appropriate that the early launch of the test coincides with Prostate Cancer Awareness month," said Dr Jon Burrows, OBD's Chief Executive Officer.
  • Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication, Journal of Clinical Oncology [online], 28:15.
  • Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, Patient, MD, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, MD–PhD, Pharmaceutical industry

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.

Key Points: 
  • Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • I am thrilled to join the Nexcella Scientific Advisory Board.”
    “We are delighted to be joined by Dr. Lentzsch on the Nexcella Scientific Advisory Board,” stated Ilya Rachman, MD PhD Executive Chairman of Nexcella.

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, MD, Patient, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, Pharmaceutical industry

Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.

Key Points: 
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “I have been fortunate to lead efforts to conduct clinical trials resulting in new treatment options for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Lentzsch.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Retrieved on: 
Thursday, August 31, 2023
FDA, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Oculocerebrorenal syndrome, University, Journal of Clinical Oncology, Hepatology, University of Naples Federico II, Liver cancer, DSM-IV codes, European Medicines Agency, IDMC, American Society of Clinical Oncology, Survival, Policy, History, WNT, Cancer, Psoriasis, ASCO, EMA, Journal, Patient, Pancreas, CANF, Treatment, TASE, Adolescence, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CKD, SLD, NYSE, HCC, Safety, Food, A3, Society, Medical imaging, Pharmaceutical industry, Cryptocurrency, Life insurance, Medicine, Genetics

In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.

Key Points: 
  • In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.
  • The FDA requested two Phase III studies and also encouraged the Company to enroll adolescent patients due to Piclidenoson’s strong safety profile demonstrated over its development history and prior clinical studies.
  • The decrease in cash during the six months ended June 30, 2023 is due to the ongoing operations of the Company.
  • The Company's consolidated financial results for the six months ended June 30, 2023 are presented in accordance with US GAAP Reporting Standards.